Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma

Abstract

The IARGI can serve as valuable biomarkers for evaluating the tumor microenvironment and predicting the prognosis of LUAD patients. Furthermore, these genes probably provide valuable guidance for establishing effective immunotherapy regimens for LUAD patients.